Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients (PREDICTOR)
Multi-centric Randomized Phase II Study of Pre-operative Afatinib (BIBW2992) Aiming at Identifying Predictive and Pharmacodynamic Biomarkers of Biological Activity and Efficacy in Untreated Non-metastatic Head and Neck Squamous Cell Carcinoma Patients
Sponsor: UNICANCER
A PHASE2 clinical study on Carcinoma, Squamous Cell of Head and Neck, this trial is completed. The trial is conducted by UNICANCER and has accumulated 11 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Apr 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE2
Status: Completed → Active Not Recruiting
▶ Show 6 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Completed PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Jul 2018 — Nov 2019 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jun 2018 — Jul 2018 [monthly]
Unknown Status PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Jan 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- UNICANCER
For direct contact, visit the study record on ClinicalTrials.gov .